Emergent BioSolutions Announces Initiation of Phase 1 Study Evaluating Its Universal Influenza Vaccine Candidate

Published on :

Emergent BioSolutions Inc. (NYSE: EBS) today announced the first participant dosed in its phase 1 study, EBS-UFV-001, evaluating the safety, tolerability, and immunogenicity of the company’s investigational universal influenza vaccine candidate. This current version of Emergent’s universal influenza vaccine candidate contains multiple components intended to induce broad and supra-seasonal immunity against influenza A viruses.

Emmes Acquires Institut Dr. Schauerte, Entering Real World Evidence Market

Published on :

Emmes, a global, full-service Clinical Research Organization (CRO) dedicated to supporting the advancement of public health and biopharmaceutical innovation, today announced that it has acquired Institut Dr. Schauerte, a CRO headquartered in Munich, Germany.  Founded in 1990, Institut Dr. Schauerte is a full-service, technology-oriented CRO that specializes in late-phase, non-interventional, and post-market clinical follow-up studies.  It has conducted more than 400 studies across a range of therapeutic areas. 

Nurturing the Growing BioHealth Capital Region Ecosystem – Reflections from the Mid-Atlantic Life Science and Biotech Summit

Collage including Bisnow event information, a photo of panelists, and networkers
Published on :

It’s no secret that the BioHealth Capital Region has blossomed into a competitive and notable life science ecosystem in recent years, with capital continuing to flow into the sector. We have much to celebrate in how far we’ve come, but we must also realize that the work is far from over. Now that our roots have been firmly established, we need to think on how we can continue to support our ecosystem so that it can flourish.

Precigen UltraCAR-T Technology Flexes its Muscles at ASH Meeting

Published on :

At the American Society of Hematology meeting earlier this month, Precigen presented positive interim data from an ongoing Phase 1/2b clinical study of PRGN-3006 UltraCAR-T in patients who have been diagnosed with relapsed or refractory (r/r) acute myeloid leukemia (AML) and higher-risk myelodysplastic syndromes (MDS). The interim study data showed what the trial investigators are calling “excellent, dose-dependent expansion.”

Novavax Receives Positive European Medicines Agency Recommendation for Conditional Marketing Authorization of its COVID-19 Vaccine

Novavax logo
Published on :

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that the European Medicines Agency (EMA) has recommended granting a conditional marketing authorization for Novavax’ COVID-19 vaccine (also known as NVX-CoV2373) to prevent COVID-19 in people from 18 years of age and older.

“There’s Gold in Them Thar Hills!” – VC Funding Floods BioHealth Capital Region in 2021

Photo of gold bars
Published on :

In the third quarter of 2021 alone, more than $400 million of private capital was invested in Maryland businesses. The money went to more than 34 different companies, according to data compiled by PitchBook. The deals brought the state to about $1.6 billion in funding for the first three-fourths of the year and placed Maryland on track to bring in about $2 billion worth of VC funding for the year. That was a significant jump over 2020, when Maryland saw about $1.26 billion in VC funding. For the industry at large in 2020, VC activity in biotechs grew by 45% to $36.6 billion.

Emergent BioSolutions Expanding Quality Assurance Team

Emergent logo with "Now Hiring" sign, photo of two Emergent employees talking in an office
Published on :

Quality assurance is a key function in the biopharma industry that provides a hands-on role in day-to-day operations. It’s a role that allows team members to maintain their fingers on the pulse of the beating heart of a drug manufacturing company. And it’s a role that’s available at one of the biggest drug manufacturing companies in the BioHealth Capital Region.

CvilleBioHub Builds a Thriving Life Sciences Ecosystem in Charlottesville

CVille Biohub Logo
Published on :

Over the past few years, even with the challenges of the COVID-19 pandemic, CvilleBioHub has thrived and grown as it continues to establish itself as one of the premiere life sciences clusters in the state of Virginia. Having launched roughly five years ago, the organization aims to double the size of the industry within the region by the year 2030, and the growth seen in the Charlottesville area over the past two years has already well-exceeded expectations.

JuneBrain Joins Thriving Medtech Community at the University of Maryland BioPark

Headshot of Samantha Scott, JuneBrain CEO
Published on :

JuneBrain is located in Baltimore and was founded by Dr. Samantha Scott in 2017. The company is a medtech startup that has the potential to improve the lives of the nearly 500 million patients suffering from neurological and retinal diseases. Dr. Scott has developed a prototype for a wearable, telehealth eye-scanning solution that allows providers to identify new disease activity outside of the clinic for patients suffering from diseases like multiple sclerosis (MS) and age-related macular degeneration (AMD), among others. 

Accellix Raises $10 Million From BroadOak Capital Partners

Published on :

SAN JOSE, Calif. & BETHESDA, Md.–(BUSINESS WIRE)–Accellix Inc., which provides quick and accurate flow cytometry results in a compact and easy-to-use platform designed for use by cell therapy companies on the manufacturing floor and at the point-of-need, today announced that it has raised $10 million from BroadOak Capital Partners.